BMZ.MU BML Inc
- Market cap
- EUR 817M
- P/E
- 18.8x
- P/B
- 1.13x
- ROE
- 6.2%
- Dividend yield
- 3.41%
- Fundamental score
- 2.3/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BMZ.MU undervalued?
Graham numberBMZ.MU trades 2.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BML Inc fundamental analysis
12 of 22 checks passedROE 0/2
Low return on equity (6.2%), below 10%.
ROA 1/1
Return on assets (4.4%) is above the industry median (-19.8%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (28.7%) is above the 5-year average (-9.3% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (28.7%) is above the industry median (3.8%).
Revenue Growth 0/2
Revenue shrank 2.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 101.2x against interest expense, well covered.
PE vs Market 0/1
PE (18.8x) is above the market median (16.6x).
PE vs Industry 0/1
PE (18.8x) is above the industry median (18.6x).
PBV 1/1
Price to book (1.1x) is below the industry median (3.1x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 21.3, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (3.4%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 64.3%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
BML Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BML Inc
BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony a…
Full company profileBML Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BML Inc annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 111B | 114B | 117B | 121B | 139B | 186B | 159B | 138B | 143B | 150B | 156B |
| Gross Profit | 39.8B | 40.5B | 42.2B | 42.3B | 54.8B | 87.0B | 61.4B | 45.6B | 45.9B | 48.7B | 52.4B |
| Operating Income | 9.33B | 9.34B | 10.5B | 9.76B | 19.9B | 48.9B | 23.9B | 9.17B | 9.36B | 10.4B | 12.0B |
| EBITDA | - | 15.1B | 16.2B | 15.3B | 26.4B | 56.2B | 30.5B | 16.3B | 17.5B | 21.2B | 12.6B |
| Net Income | 5.95B | 5.99B | 6.65B | 6.38B | 13.7B | 33.7B | 15.6B | 6.03B | 6.26B | 7.75B | 7.92B |
| EPS | 140 | 141 | 156 | 157 | 337 | 845 | 399 | 155 | 161 | 207 | 211 |
| Balance Sheet | |||||||||||
| Total Assets | 104B | 109B | 116B | 116B | 139B | 179B | 169B | 171B | 178B | 183B | 180B |
| Total Liabilities | 33.6B | 33.2B | 34.8B | 35.9B | 46.1B | 57.5B | 42.2B | 40.9B | 43.7B | 51.1B | 48.4B |
| Shareholders' Equity | 67.3B | 72.6B | 77.1B | 76.2B | 88.4B | 116B | 122B | 126B | 129B | 128B | 127B |
| Cash & Short-term Investments | 41.3B | 46.3B | 51.9B | 51.2B | 63.5B | 92.1B | 86.5B | 74.1B | 67.6B | 68.0B | 53.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 11.3B | 12.1B | 12.5B | 12.8B | 19.6B | 45.6B | 11.7B | 14.4B | 15.8B | 20.7B | - |
| Capital Expenditure | 3.12B | 2.81B | 2.60B | 2.94B | 3.09B | 5.69B | 6.46B | 20.9B | 16.7B | 10.1B | 0.00 |
| Free Cash Flow | - | 7.93B | 8.67B | 8.66B | 15.4B | 38.5B | 5.28B | -6.48B | -849M | 10.6B | - |
| Ratios | |||||||||||
| ROE | 8.8% | 8.2% | 8.6% | 8.4% | 15.5% | 29.0% | 12.7% | 4.8% | 4.8% | 6.1% | 6.2% |
| ROA | 5.7% | 5.5% | 5.7% | 5.5% | 9.9% | 18.8% | 9.2% | 3.5% | 3.5% | 4.2% | 4.4% |
| Net Profit Margin | 5.3% | 5.3% | 5.7% | 5.3% | 9.9% | 18.1% | 9.8% | 4.4% | 4.4% | 5.2% | 5.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BML Inc dividends
- Dividend yield
- 3.41%
- Forward dividend
- 0.71 EUR
- Payout ratio
- 64.3%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 4.98B | 133 | 64.3% |
| 2025 | JPY 3.51B | 90 | 56.0% |
| 2024 | JPY 3.90B | 100 | 64.6% |
| 2023 | JPY 4.96B | 127 | 31.9% |
| 2022 | JPY 3.46B | 87 | 10.2% |
| 2021 | JPY 1.83B | 45 | 13.3% |
| 2020 | EUR 1.66B | 41 | 26.1% |
| 2019 | EUR 1.55B | 36 | 23.4% |
| 2018 | EUR 1.49B | 35 | 24.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Aug 29, 2016.
Who owns BML Inc
- Insiders 42.34%
- Institutions 19.14%
- Public & others 38.52%
- Shares outstanding 37.5M
- Free float 19.7M
BML Inc company profile
- Company name
- BML Inc
- Ticker
- BMZ.MU
- Exchange
- Munich Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,612
- Fiscal year end
- March
- Address
- 5-21-3 Sendagaya, Tokyo, Japan, 151-0051
- Phone
- 81 3 3350 0111
- Website
- bml.co.jp
About BML Inc
BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds. In addition, the company is involved in manufacturing and supply services for medical equipment and supplies; real estate leasing and insurance agency business; providing food hygiene inspection and food consulting services; and dispensing pharmacy services. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
BML Inc management
7- Mr. Kensuke KondoPresident & Representative Director · born 1966
- Mr. Hideaki OsawaExec. Officer, Div Mangr of Mktg. & Dept. Mangr of Proposal & Clinical Trial Mktg and Dir · born 1964
- Mr. Nobuki AraiVP & Representative Director · born 1960
- Masami KondoSr.Mag Exec. Offi Div. Mgr of In-Hospital Testing, Dept. Mgr of 2nd In-Hospital Testing and Director · born 1965
- Mr. Kenji ShibataSenior Managing Executive Officer, Div Manager of BML Testing Division & Director · born 1959
- Mr. Yuji YamashitaExecutive Officer, Division Manager of System Division & Director · born 1965
- Hiroyuki KigoshiManaging Executive Officer